01.11.2012
- Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators...
04.04.2011
- French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...
30.03.2011
- Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...
08.03.2011
- Genzyme Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final - and stands to earn...
03.02.2011
- French drugmaker Sanofi-Aventis could announce a deal to buy U.S. biotech Genzyme early next week if final negotiations between the companies go smoothly, Le Figaro reported on...
02.02.2011
- France's Sanofi-Aventis has agreed to raise its bid for Genzyme Corp to the low $70s-per-share range, plus a milestone payment based on the performance of an experimental drug, a...
01.02.2011
- U.S. biotech Genzyme and French drugmaker Sanofi-Aventis have reached agreement in principle on the terms of a deal under which Sanofi would acquire Genzyme, three sources familiar...
27.01.2011
- A proxy battle for control of Genzyme is unlikely, given the progress being made in discussions with Sanofi-Aventis, the U.S. biotech group's chief executive said on Thursday...
